Press Releases

 
Press Releases
  Date Title and Summary View
Jun 4, 2012
AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that data from Phase 1 and Phase 1B studies evaluating NLG8189 (D-1MT, 1-methyl-D-tryptophan or d-1-Methyltryptophan) will be presented in an oral presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held in ...
Jun 4, 2012
Jun 4, 2012
Jun 4, 2012
AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announced its HyperAcute® Lung (tergenpantucel-L) immunotherapy wil...
Jun 4, 2012
AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announces that its HyperAcute® Pancreas (algenpantucel-L) Immunotherapy wi...
Jun 1, 2012
AMES, Iowa, June 1, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced results from a Phase 2 investigator-initiated study of NewLink's HyperAcute® Melanoma immunotherapy product candidate in combination with pegylated interferon (Sylatro...
May 30, 2012
AMES, Iowa, May 30, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and Chief Executive Officer, will present at the Jefferies 2012 Global Healthcare Conference in New York on Wednesday, June 6, 2012, at 4:30 p.m. (EDT). Dr. Link's presentation will include an update from the American Society ...
May 22, 2012
AMES, Iowa, May 22, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), today announced that Phase 2 data from its investigational HyperAcute® Pancreas immunotherapy clinical trial in surgically resected pancreas cancer patients will be presented at the 53rd Annual Meeting of the Society for Surgery of the Alimentary. The deta...
May 10, 2012
AMES, Iowa, May 10, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the first quarter of 2012, and provided an update on the progress of its clinical development programs. ...
Apr 24, 2012
AMES, Iowa, April 24, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that the United States Patent & Trademark Office (USPTO) has allowed broad claims to oral pharmaceutical compositions comprising 1-methyl-D-tryptophan (D-1MT) (US Serial No. 12/175,538) and also to oral pharmaceutical compositions comprising 1-...
Page: FirstPrevious ...
16
NextLast
= add release to Briefcase